Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therapy lenacapavir is 100% effective in preventing HIV in women.   Notably, lenacapavir was shown to be superior to once-daily oral Truvada, which is one of several medications currently used to treat HIV and to prevent HIV infection, known as pre-exposure prophylaxis (PrEP).

Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial

Jazz Pharmaceuticals

Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.

2 Pharma Stocks Moving in Different Directions Today

Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective

Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.

Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial

Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.

Gilead's HIV prevention treatment found 100% effective in late-stage trial

Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truvada.

Gilead's long-acting HIV drug superior to daily pill Truvada in study

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. PURPOSE 1 met its key efficacy endpoints of superiority of twice-yearly lenacapavir to once-daily oral Truvada® (emtricitabine 200mg and tenofo.

Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Amgen

bluebird bio

Bristol-Myers

Neurocrine Biosciences

Novartis

Ultragenyx Pharmaceutical

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

Gilead stock reversed lower Monday after confirming it's testing a popular weight-loss mechanism as a treatment for a liver disease.

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender

Enbridge

There are always opportunities in this market for stocks despite high total market valuation. Gilead Sciences offers strong growth potential with a well-covered dividend yield of 4.8% and a promising pipeline. Enbridge provides stable income with a 7.6% dividend yield, strong growth prospects, and trades below historical valuations.

2 June Bargains With Up To 7.6% Yield

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

A success would be a gamechanger for the biotech company known for its HIV treatments.

Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual.

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

The latest trading day saw Gilead Sciences (GILD) settling at $63.56, representing a -1.21% change from its previous close.

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead's June 4th press release reported in the San Francisco Chronicle

Law Firms Speaking Out For The Thousands of California HIV Patients They Represent After Gilead's $40 Million Settlement Prompts Moral Reckoning for the HIV Community

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining.

Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

Cisco Systems

Starbucks

24/7 Insights The Nasdaq is up a stunning 14.5% this year after a massive 43% gain in 2023.

3 No-Brainer Nasdaq Stocks to Buy in June

Organon & Co

Pfizer

Gilead Sciences is a safe, reliable dividend stock. Organon pays a high dividend yield and has been a big winner for investors this year.

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of.

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

Gilead Sciences, Inc. (NASDAQ:GILD ) Jefferies 2024 Global Healthcare Conference June 5, 2024 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Michael Yee I am very happy to have up here with us Chief Medical Officer of Gilead, Merdad Parsey. It's great to have you with us fresh off of four or five days of ASCO.

Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference

Kraft Heinz

Walgreens

Walgreens has lost some 70% of its value, and the stock now yields 6.5%. Kraft Heinz has experienced a similar slump, and its shares offer a 4.6% yield.

Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?

Banco de Chile

Duke Energy

National Storage Affiliates Trust

Realty Income Corp

OneMain Hld

Southern Company

The stock market continues making new highs seemingly almost every week. Investors are thrilled about new developments in fields such as semiconductors and artificial intelligence that could lead to tremendous earnings growth and resulting share price appreciation.

The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream

British American Tobacco

Comcast

AT&T

Verizon

Finding good dividend stocks to buy amid market turbulence is essential in today's investing environment to maximize profits and minimize risks. These seven dividend stocks to buy have performance indicators that lead in a variety of industries.

7 Dividend Stocks to Invest In for a Lifetime of Income

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants f.

Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

Bank of America

Hess

Hedge fund operator Ken Griffin is the founder and CEO of Citadel, one of the world's most successful alternative investment firms. It has over $103 billion in assets under management (AUM) and Griffin likes to cast a wide net when making investments.

News for Gilead Sciences Stock (GILD)